Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07545226 · ClinicalTrials.gov registry record · Phase 1
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
A Phase 1 study, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 400
- Enrollment target
NCT07545226 is a Phase 1 study that is actively recruiting participants, run by Amgen. The registered enrollment target is 400 participants.
The verdict
NCT07545226, a Phase 1 study, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 400 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the pharmacokinetics (PK) of two evolocumab drug products in healthy participants.
Interventions
- DRUG Evolocumab Drug Substance A (Test)
- DRUG Evolocumab Drug Substance B (Reference)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-04-21 |
| Est. Completion | 2026-09-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07545226
The ClinicalTrials.gov registry entry for NCT07545226 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Evolocumab Drug Substance A (Test) is the first listed.
NCT07545226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07545226 about?
NCT07545226 is a clinical study titled "Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.". The primary objective of this trial is to evaluate the pharmacokinetics (PK) of two evolocumab drug products in healthy participants.
What is the current status of trial NCT07545226?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 400 participants. The study started on 2026-04-21. Estimated completion is 2026-09-08.
What interventions are being tested in trial NCT07545226?
The interventions under investigation include: Evolocumab Drug Substance A (Test) (DRUG), Evolocumab Drug Substance B (Reference) (DRUG).
Who is sponsoring clinical trial NCT07545226?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.